Shares of Eli Lilly gains momentum on news of an FDA drug approval. CNBC's Seema Mody reports.
CNBC’s Meg Tirrell talks to Kenneth Frazier, Merck CEO, at the fifth annual Forbes Healthcare Summit in New York about the future of drug pricing under the Trump administration as well as Alzheimer’s research.
The "Fast Money" traders weigh in on Eli Lilly and Juno Therapeutics, following failed drug trials.
Vamil Divan, Credit Suisse senior analyst, discusses Eli Lilly's failed Alzheimer's drug trial and the effect on its stock price.
Ronny Gal, Bernstein senior analyst, weighs in on Eli Lilly's failed Alzheimer's drug study results.
The “Fast Money Halftime Report” traders weigh in on the biotech sector, with Eli Lilly and Juno Therapeutics stocks dropping significantly.
Eli Lilly, Urban Outfitters and Alphabet stocks are making headlines this Wednesday morning.
Lilly shares tumble after its Alzheimer drug study did not meet its goals, reports CNBC's Meg Tirrell. Obviously we are disappointed but we remain committed to Alzheimer's disease, says John Lechleiter, Eli Lilly CEO. And David Ricks, Eli Lilly incoming CEO, weighs in on the company's future growth prospects.
CNBC's Meg Tirrell reports on Eli Lilly's Alzheimer's drug trial plans and speaks to incoming CEO David Ricks.
CNBC's Meg Tirrell reports on Eli Lilly's drug being tested to treat Alzheimer's disease.